Stifel Nicolaus assumed coverage on shares of Legend Biotech (NASDAQ:CALT) in a research report released on Tuesday morning, The Fly reports. The firm issued a buy rating and a $28.00 price objective on the stock.
NASDAQ CALT opened at $19.95 on Tuesday. Legend Biotech has a fifty-two week low of $19.00 and a fifty-two week high of $24.97.
Legend Biotech Company Profile
Recommended Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.